Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company ChemoCentryx
With that in mind, let's take a closer look at ChemoCentryx's business and see what CAPS investors are saying about the stock right now.
|Headquarters (Founded)||Mountain View, Calif. (1997)|
|Market Cap||$425.4 million|
|Trailing-12-Month Revenue||$29.6 million|
|Management||Founder/Chairman/CEO Dr. Thomas Schall
CFO Susan Kanaya
|Trailing-12-Month Return on Equity||(10.9%)|
|Cash/Debt||$131.6 million / $1.2 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, all 18 members who have rated ChemoCentryx believe the stock will outperform the S&P 500 going forward.
I see ChemoCentryx as undervalued at this level given their multiple compounds in advanced clinical trials for various indications and a strong partnership with [GlaxoSmithKline].
Having IPO'd just a few months ago, ChemoCentryx is weakly followed and lacks objective vetting. However, their chemokine receptor focus has been extensively validated by academic research and has been addressed by other biopharmas. ...
The company is somewhat reticent when it comes to updating the progress of ongoing studies, but I believe once the street becomes more aware of the four ongoing SHIELD phase III trials being run by Glaxo for moderate-to-severe Crohn's the [market cap] will break 600M. Meanwhile the company is well-capitalized with a strong balance sheet.
If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, ChemoCentryx may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Abbott. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.